SHMT2 and adenocarcinoma: Kaplan-Meier survival analysis of clinical tumor samples revealed that patients with adenocarcinoma (AC), squamous cell carcinoma, and SCLC exhibiting high SHMT2 expression had a significantly lower overall survival (OS) than those with low SHMT2 expression (Yao et al., 2021).